Beta Bionics, Inc.

NASDAQ:BBNX

Medical - Equipment & Services

Healthcare
$14.33 +3.18%

+$0.42 today

Market cap
$644.70M
Beta
3.39
P/E (TTM)
-9.1
EPS (TTM)
-$1.50
52W Low $8.80High $32.71

Volume 1.38M

Average 0.99M

BBNX Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Beta Bionics, Inc.NASDAQ: BBNX

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses grows, but more slowly than its trailing trend

Q1 FY2026 operating expenses of $40.71M rose 47.4% year over year, behind the +52.4% change in trailing-twelve-month operating expenses. Sequentially, it rose 16.1% from the prior quarter. Over 3 fiscal years it compounded at +24.4% a year.

Context

  • Operating expenses amounted to 126.9% of revenue in FY2025, up 2.3 pp from a year earlier.
  • Operating expenses increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +47.4% toward the trailing-twelve-month pace of +52.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$40.71M+16.1% QoQ
Last fiscal yearDec 2025
$127.22M+56.8% YoY
LTMMar 2026
$140.31M+52.4% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+47.4%——
1 year+56.8%——
3-year CAGR+24.4%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
127.22M USD
Year-over-year change
+56.8%
3-year CAGR
+24.4%

Operating Expenses vs competitors

How BBNX compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +52.4% is the 2nd highest of 7, against a peer median of +5.3%.
  • Operating expenses amounts to 127.3% of revenue for BBNX, versus a peer median of 53.8%.
BBNX Competitors
Operating Expenses for BBNX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 123.58B DKK+3.8%+18.5%37.5%
DXCMDexCom, Inc.LTM Jun 2026$1.97B USD+6.8%+8.2%39.5%
MMEDMiniMed Group, Inc. Common StockLTM Jul 2026$1.72B USD—+5.8%53.3%
PODDInsulet CorporationLTM Jun 2026$1.65B USD+31.1%+24.1%54.2%
TNDMTandem Diabetes Care, Inc.LTM Mar 2026$645.41M USD-6.7%+6.4%62.8%
MNKDMannKind CorporationLTM Mar 2026$260.65M USD+81.1%+32.8%72.2%
BBNXBeta Bionics, Inc.LTM Mar 2026$140.31M USD+52.4%+24.4%127.3%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$14.22M USD-0.8%-29.6%—
Peer median (excluding BBNX) —+5.3%+8.2%53.8%

Competitors are the stored peer set for BBNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue179K12M65.12M100.25M
Cost of Revenue05.69M29.24M44.71M
Gross Profit179K6.31M35.89M55.54M
Gross Margin100.0%52.6%55.1%55.4%
Research & Development31.43M17.94M26.18M34.79M
Selling, General & Admin33.5M24.22M54.96M92.43M
Operating Expenses66.02M42.16M81.14M127.22M
Depreciation & Amortization1.35M1.23M1.15M2.88M
EBITDA(63.4M)(42.87M)(53.61M)(70.32M)
EBITDA Margin-35418.4%-357.4%-82.3%-70.1%
Operating Income(65.84M)(35.85M)(45.25M)(71.68M)
Operating Margin-36784.4%-298.9%-69.5%-71.5%
Interest Income196K1.78M3.91M10.93M
Interest Expense14K000
Other Income / Expenses1.09M(8.25M)(9.51M)(1.52M)
Income Before Tax(64.75M)(44.1M)(54.76M)(73.2M)
Pre-Tax Margin-36173.7%-367.6%-84.1%-73.0%
Income Tax Expense0001K
Net Income(64.75M)(44.1M)(54.76M)(73.2M)
Net Margin-36173.7%-367.6%-84.1%-73.0%
EPS (Basic)(12.96)(8.31)(8.60)(1.81)
EPS (Diluted)(12.96)(8.31)(8.60)(1.81)
Weighted Avg Shares5M5.3M6.37M40.53M
Weighted Avg Shares (Diluted)5M5.3M6.37M40.53M

Beta Bionics, Inc.

NASDAQ:BBNX

Intrinsic Alpha fair value

Locked

Current Price

$14.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.